SAN FRANCISCO, July 27 /PRNewswire-FirstCall/ — YesDTC
Holdings, Inc. (OTC Bulletin Board: YESD), a direct-to-consumer
marketer and global distributor of consumer goods and products and
BioElectronics Corp. (Pink Sheets: BIEL), manufacturers of
innovative pain relieving medical devices, today announced the
companies have received notification of the pending review by
Japanese government medical device regulators for the
ActiPatch™ and Allay™ Menstrual Relief products.
This review will take place on Wednesday, July 28th.
The initial analysis by YesDTC’s attorneys has been very
favorable toward the Company’s ability to begin marketing in Japan as several similar devices are
already on the market. This regulatory review is designed to
verify that Japanese regulatory agencies will place ActiPatch and
Allay in the same category as these currently marketed devices or
if additional information and or testing will be required.
BioElectronics and YesDTC recently announced several important
product line enhancements specifically tailored to suit the needs
of the highly discerning and quality conscious Japanese
marketplace. Additionally, upon release, BioElectronics will
make the recently announced back pain belt available to the
Japanese marketplace.
Andrew Whelan, CEO of
BioElectronics commented, “We view the Japanese market as being
highly significant to our future success. There is a history
of Japanese regulators closely mirroring the medical device
classifications that had earlier occurred within the European
Union, where we are a Class IIa device. This pending review,
which will take place this week, should offer us a great deal of
information about
‘/>”/>
SOURCE